HOME >> MEDICINE >> NEWS
Use of estrogen by postmenopausal women does not increase risk of breast cancer

CHICAGO Postmenopausal women treated with estrogen therapy for seven years did not experience an increased risk of breast cancer, according to a study in the April 12 issue of JAMA.

The Women's Health Initiative (WHI) Estrogen-Alone trial, which randomized women with prior hysterectomy to conjugated equine estrogens (CEE) or placebo, was stopped earlier than planned because of increased stroke incidence and no reduction in risk of coronary heart disease. In contrast to substantial epidemiological evidence associating exogenous (originating externally) estrogens with increased breast cancer incidence, preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports.

Marcia L. Stefanick, Ph.D., of Stanford University, Stanford, Calif., and colleagues with the WHI study, analyzed the data from the CEE-alone group of the WHI study to determine the effects of CEE on breast cancers and mammographic findings. The study included 10,739 postmenopausal women aged 50 to 79 years with prior hysterectomy who were randomized to CEE or placebo at 40 U.S. clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included. Participants received a dose of 0.625 mg/d of CEE or an identical-appearing placebo.

In an analyses of all events (n = 237 cases) occurring prior to intervention termination, after an average follow-up of 7.1 years, nonsignificant reductions were observed for invasive breast cancer (20 percent lower rate) and for total breast cancer (18 percent lower rate) in women randomized to CEE, when compared to the placebo group. The annualized rates were 0.28 (104 cases in the CEE group) and 0.34 (133 cases in the placebo group). In further analyses, fewer breast cancers with localized disease were diagnosed
'"/>

Contact: Susan Ipaktchian
650-725-5375
JAMA and Archives Journals
11-Apr-2006


Page: 1 2

Related medicine news :

1. COX inhibitors may weaken protective qualities of estrogen hormone therapy
2. Study describes action of estrogen in protecting bone
3. New path from estrogen to survival in breast cancer cells described
4. High estrogen levels associated with dementia in older men
5. Ultra low-dose estrogen shown safe for post-menopausal women
6. Gabapentin cools hot flashes as well as estrogen
7. Study uncovers significant functional differences of novel estrogen receptor
8. Early estrogen exposure leads to later prostate cancer risk
9. Long-term estrogen therapy linked to breast cancer risk
10. Low estrogen levels in men linked to increased risk for hip fracture
11. Benefit of chemotherapy in breast cancer depends on estrogen-receptor status

Post Your Comments:
(Date:4/1/2015)... (PRWEB) April 01, 2015 Pricing Healthcare ... last several months, bring coverage to a third of all ... states of Massachusetts, Kansas, and Iowa, and the first dedicated eye ... center in Dallas, TX was also added. , In addition, the ... to and general interest in the platform continue to grow across ...
(Date:4/1/2015)... With so much wet weather over the past ... their time indoors. When all this time is spent inside, ... latest article from Clean Crawls offers excellent advice to ... , One of the ways to improve the air ... The article states that, “Toluene, Xylene, and Benzene are all ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 "Giving credit ... to form. Its rewards are inestimable." - Loretta Young ... individuals in the water resources profession. The Call ... Please consider nominating yourself, a colleague, or organization for ... 2015. Learn more about the AWRA Awards and view ...
(Date:4/1/2015)... Decora Preset 30 Minute Countdown Timer, a ... Hardware City.’ The product helps in automatically switching off any ... the related electronic device is automatically turned off after the ... said, “We are glad that this amazing product is now ... Timer Switch in just a few clicks. The product has ...
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading provider ... and population health arenas, is pleased to announce a ... is fully integrated with the ACUITY platform. , The ... ET, will be led by Jeff Frater, RN, BSN, ... the feature-rich portal as well as the importance of ...
Breaking Medicine News(10 mins):Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:3 Simple Ways to Improve Home Air Quality Listed by Clean Crawls in Latest Article 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 3Health News:Leviton Decora Preset 30 Minute Countdown Timer Available On TheHardwareCity.com 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3
(Date:4/1/2015)... 1, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, ... and cholesterol gallstones, today announced that it has ... of Clinical Operations. Mr. Tonelli brings ... development and regulatory affairs.  From 2005 to 2014, ...
(Date:4/1/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... company GmbH.  scil animal care is a highly specialized ... and services to veterinarians primarily in North ... on January 19, 2015. scil animal care ...
(Date:3/31/2015)... , March 31, 2015 Neurocrine Biosciences, Inc. ... entered into an exclusive collaboration and licensing agreement for ... in Japan and other select ... Mitsubishi Tanabe intends to initially develop NBI-98854 in ... Huntington,s disease and tardive dyskinesia. Neurocrine retains full commercial ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3Henry Schein Completes Acquisition of scil animal care 2Henry Schein Completes Acquisition of scil animal care 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
Cached News: